Quest, Beth Israel, Weill Cornell Collaborate on MDx for Organ Renal Transplant Rejection | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics has teamed up with Beth Israel Deaconess Medical Center and Weill Cornell Medical College to launch a molecular blood test for identifying renal organ transplant rejection.

Quest has also formed R&D collaboration deals with Beth Israel Deaconess and Weill Cornell in the area of renal transplantation, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.